Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope

ABSTRACT The membrane-proximal region of the ectodomain of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) is the target of three of the five broadly neutralizing anti-HIV-1 antibodies thus far isolated. We have determined crystal structures of the antigen-binding fragment for one of these antibodies, 2F5, in complex with 7-mer, 11-mer, and 17-mer peptides of the gp41 membrane-proximal region, at 2.0-, 2.1-, and 2.2-Å resolutions, respectively. The structures reveal an extended gp41 conformation, which stretches over 30 Å in length. Contacts are made with five complementarity-determining regions of the antibody as well as with nonpolymorphic regions. Only one exclusive charged face of the gp41 epitope is bound by 2F5, while the nonbound face, which is hydrophobic, may be hidden due to occlusion by other portions of the ectodomain. The structures reveal that the 2F5 antibody is uniquely built to bind to an epitope that is proximal to a membrane surface and in a manner mostly unaffected by large-scale steric hindrance. Biochemical studies with proteoliposomes confirm the importance of lipid membrane and hydrophobic context in the binding of 2F5 as well as in the binding of 4E10, another broadly neutralizing antibody that recognizes the membrane-proximal region of gp41. Based on these structural and biochemical results, immunization strategies for eliciting 2F5- and 4E10-like broadly neutralizing anti-HIV-1 antibodies are proposed.

[1]  K. Subbarao,et al.  pH-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell Transfer through DC-SIGN , 2004, Journal of Virology.

[2]  H. Katinger,et al.  The Long Third Complementarity-Determining Region of the Heavy Chain Is Important in the Activity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 , 2004, Journal of Virology.

[3]  Wayne A Hendrickson,et al.  Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Shibo Jiang,et al.  Binding of the 2F5 Monoclonal Antibody to Native and Fusion-Intermediate Forms of Human Immunodeficiency Virus Type 1 gp41: Implications for Fusion-Inducing Conformational Changes , 2004, Journal of Virology.

[5]  Christoph Grundner,et al.  Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.

[6]  Gennaro Ciliberto,et al.  Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. , 2003, Journal of molecular biology.

[7]  Ping Zhu,et al.  Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition , 2003, Science.

[8]  Dennis R. Burton,et al.  Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design , 2003, Journal of Virology.

[9]  G. McGaughey,et al.  HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. , 2003, Biochemistry.

[10]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[11]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Andrew C. R. Martin,et al.  Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. , 2003, Journal of molecular biology.

[13]  B. Korber,et al.  HIV sequence compendium 2002 , 2002 .

[14]  Peter D. Kwong,et al.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.

[15]  G. Lewis,et al.  Antigenic Properties of the Human Immunodeficiency Virus Transmembrane Glycoprotein during Cell-Cell Fusion , 2002, Journal of Virology.

[16]  Y. Hayek,et al.  A monomeric 3(10)-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41. , 2002, Biochemistry.

[17]  E. Arnold,et al.  Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints. , 2002, The journal of peptide research : official journal of the American Peptide Society.

[18]  J. Mascola,et al.  Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells , 2002, Journal of Virology.

[19]  J. Sodroski,et al.  Solid-Phase Proteoliposomes Containing Human Immunodeficiency Virus Envelope Glycoproteins , 2002, Journal of Virology.

[20]  K. MacDonald,et al.  Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraint. , 2002, Vaccine.

[21]  H. Katinger,et al.  A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. , 2001, AIDS research and human retroviruses.

[22]  C. E. Parker,et al.  Fine Definition of the Epitope on the gp41 Glycoprotein of Human Immunodeficiency Virus Type 1 for the Neutralizing Monoclonal Antibody 2F5 , 2001, Journal of Virology.

[23]  Paul W. H. I. Parren,et al.  Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.

[24]  J. Sodroski,et al.  Ligand Binding Characteristics of CXCR4 Incorporated into Paramagnetic Proteoliposomes* , 2001, The Journal of Biological Chemistry.

[25]  H. Katinger,et al.  Cross-Neutralizing Human Monoclonal Anti-HIV-1 Antibody 2F5: Preparation and Crystallographic Analysis of the Free and Epitope-Complexed Forms of its F ab Fragment , 2001 .

[26]  Garrett M. Morris,et al.  Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design , 2001, Science.

[27]  H. Vogel,et al.  The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles. , 2001, Biochemistry.

[28]  C Leclerc,et al.  Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. , 2000, Vaccine.

[29]  Ying-hua Chen,et al.  Induction of high level of specific antibody response to the neutralizing epitope ELDKWA on HIV-1 gp41 by peptide-vaccine☆ , 2000, Peptides.

[30]  H. Katinger,et al.  Stable recombinant expression of the anti HIV-1 monoclonal antibody 2F5 after IgG3/IgG1 subclass switch in CHO cells. , 2000, Biotechnology and bioengineering.

[31]  Ying-hua Chen,et al.  Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody , 2000, Immunological investigations.

[32]  R. Blumenthal,et al.  Role of the Membrane-Proximal Domain in the Initial Stages of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein-Mediated Membrane Fusion , 1999, Journal of Virology.

[33]  J. Shendure,et al.  Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. , 1999, Vaccine.

[34]  D E McRee,et al.  XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. , 1999, Journal of structural biology.

[35]  E. Hunter,et al.  A Conserved Tryptophan-Rich Motif in the Membrane-Proximal Region of the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Is Important for Env-Mediated Fusion and Virus Infectivity , 1999, Journal of Virology.

[36]  P. D. Kwong,et al.  Use of cryoprotectants in combination with immiscible oils for flash cooling macromolecular crystals , 1999 .

[37]  H. Katinger,et al.  Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. , 1998, AIDS research and human retroviruses.

[38]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[39]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[40]  H. Katinger,et al.  Baculovirus surface display: construction and screening of a eukaryotic epitope library. , 1998, Nucleic acids research.

[41]  C. Weiss,et al.  Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.

[42]  M. Roederer,et al.  8 color, 10-parameter flow cytometry to elucidate complex leukocyte heterogeneity. , 1997, Cytometry.

[43]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[44]  Deborah Fass,et al.  Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.

[45]  H. Katinger,et al.  Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. , 1996, The Journal of general virology.

[46]  A. Trkola,et al.  Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5 , 1996, AIDS.

[47]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[48]  G. Cohen,et al.  Interactions of protein antigens with antibodies. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  A. Trkola,et al.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.

[50]  C. Barbas,et al.  Protection against HIV‐1 infection in hu‐PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4‐binding site , 1995, AIDS.

[51]  Q. Sattentau,et al.  Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. , 1995, Virology.

[52]  A. Trkola,et al.  A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. , 1994, AIDS research and human retroviruses.

[53]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[54]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[55]  A. Trkola,et al.  Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS , 1994, Journal of virology.

[56]  J. Thornton,et al.  Satisfying hydrogen bonding potential in proteins. , 1994, Journal of molecular biology.

[57]  E. Emini,et al.  Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[58]  A. Trkola,et al.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. , 1994, AIDS research and human retroviruses.

[59]  G Himmler,et al.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.

[60]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[61]  K. Sharp,et al.  Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons , 1991, Proteins.

[62]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[63]  I. Wilson,et al.  Applications of the streak seeding technique in protein crystallization , 1991 .

[64]  Robin A. Weiss,et al.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients , 1985, Nature.

[65]  M. L. Connolly Analytical molecular surface calculation , 1983 .

[66]  E A Merritt,et al.  Raster3D: photorealistic molecular graphics. , 1997, Methods in enzymology.

[67]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.